Jack Ragheb Email

SVP Translational Sciences and Medicine . NexImmune

Current Roles

Employees:
45
Revenue:
$7M
About
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIMâ„¢ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body's own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient's immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient's body.
NexImmune Address
9119 Gaither Road
Gaithersburg, MD
United States
NexImmune Email

Past Companies

NexImmune, Inc.Senior Vice President Translational Sciences and Medicine
National Institutes of HealthExperimental Transplantation and Immunology Branch
Eli Lilly and CompanySenior Medical Fellow for Immunology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.